News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III                   Maria Platsis
Executive Vice President                Senior Director of Corporate Development
Chief Administrative Officer            and Investor Relations
(609) 936-2481                          (609) 936-2333
jhenneman@Integra-LS.com                mplatsis@Integra-LS.com


                Integra LifeSciences' Proposed Acquisition of the
    Radionics Division of Tyco Healthcare Group, L.P. Clears Antitrust Review


Plainsboro, New Jersey / December 12, 2005 / -- Integra LifeSciences Holdings
Corporation (NASDAQ: IART) announced today that the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to
its pending acquisition of the assets of the Radionics Division of Tyco
Healthcare Group, expired on December 9, 2005. On September 7, 2005, Integra
LifeSciences announced that it had agreed to acquire the Radionics assets for
$80 million in cash, subject to certain adjustments.


The closing of the acquisition remains subject to other customary conditions,
including the completion of a carve-out audit for the Radionics business for the
fiscal year ended September 30, 2005. We currently expect the transaction to
close in the first quarter of 2006.


Integra LifeSciences Holdings Corporation is a diversified medical technology
company that develops, manufactures, and markets medical devices for use in a
variety of applications. The primary applications for our products are
neurosurgery, reconstructive surgery and general surgery. Integra is a leader in
applying the principles of biotechnology to medical devices that improve
patients' quality of life. Our corporate headquarters are in Plainsboro, New
Jersey, and we have manufacturing and research facilities located throughout the
world. We have approximately 1,300 employees. Please visit our website at
(http://www.Integra-LS.com).


This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning expectations for the
timing of the closing of pending acquisitions. Such forward-looking statements
involve risks and uncertainties that could cause actual results to differ
materially from predicted or expected results. Among other things, the
fulfillment of all requisite closing conditions could affect the timing of this
acquisition. In addition, the economic, competitive, governmental, technological
and other factors identified under the heading "Factors That May Affect Our
Future Performance" included in the Business section of Integra's Annual Report
on Form 10-K for the year ended December 31, 2004 and information contained in
subsequent filings with the Securities and Exchange Commission could affect
actual results.


Source: Integra LifeSciences Holdings Corporation